ERBB2 and breast cancer: It may occur in the sequential administration of agents with overlapping working mechanisms, such as receptor tyrosine kinase erbB-2 (HER2)-targeting agents trastuzumab+pertuzumab and trastuzumab-emtansine (T-DM1) in breast cancer (BC).